The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least
Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a fu
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh